Biomarkers of Inflammation and Endothelial Dysfunction in Patients With Myocardial Infarction With Non-obstructive Coronary Arteries
IMACORN-INFLI
1 other identifier
observational
400
1 country
1
Brief Summary
Around 10% of patients with myocardial infarction (MI) present with nonobstructive coronary arteries (MINOCA) which pathophysiology is often uncertain. The aim of the study is to evaluate inflammation and endothelial dysfunction biomarkers in MINOCA patients during both acute and stable phases, comparing them with those with MI and obstructive coronary arteries (MICAD).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Oct 2020
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 22, 2024
CompletedFirst Submitted
Initial submission to the registry
May 27, 2024
CompletedFirst Posted
Study publicly available on registry
June 6, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
May 31, 2025
CompletedJune 6, 2024
May 1, 2024
3.6 years
May 27, 2024
May 31, 2024
Conditions
Outcome Measures
Primary Outcomes (3)
Levels of interleukin-6 (pg/ml) and tumor necrosis factor-alpha (pg/ml)
Levels of interleukin-6 (pg/ml) and tumor necrosis factor-alpha (pg/ml) will be determined.
At three time points: within the 24 hours from the onset of pain, on the 5th day of admission, and two months after MI.
Levels of endhotelial disfunction biomarkers
Levels of asymmetric dimethylarginine will be determined
At three time points: within the 24 hours from the onset of pain, on the 5th day of admission, and two months after MI.
Levels of high-sensitivity C-reactive protein (mg/L)
Levels of high-sensitivity C-reactive protein (mg/L) will be determined.
t three time points: within the 24 hours from the onset of pain, on the 5th day of admission, and two months after MI.
Study Arms (2)
MICAD
Patients with Myocardial Infarction and Obstructive Coronary Arteries
MINOCA
Patients with Myocardial Infarction and Non-obstructive Coronary Arteries
Interventions
Patients were classified as MICAD or MINOCA by the presence or absence of an epicardial vessel with ≥50% stenosis after performing a coronariography.
Eligibility Criteria
Patients older than 18 years old admitted to our hospital with Myocardial Infarction and undergo a coronariography.
You may qualify if:
- Patients admitted with Myocardial Infarction and undergo a coronariography
- Patients must sign informed consent.
You may not qualify if:
- Patients who don´t sign informed consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hospital Universitario de Getafe
Getafe, Madrid, 28905, Spain
Biospecimen
Serum, plasma, urine
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Cardiologist
Study Record Dates
First Submitted
May 27, 2024
First Posted
June 6, 2024
Study Start
October 1, 2020
Primary Completion
May 22, 2024
Study Completion
May 31, 2025
Last Updated
June 6, 2024
Record last verified: 2024-05
Data Sharing
- IPD Sharing
- Will not share